91 research outputs found
Safety and Efficacy of Oral Mirodenafil in Mexican with Erectile Dysfunction
Abstract Erectile dysfunction is treated with 5-phospodiesterase inhibitors as Mirodenafil, which has shown its efficacy and safety in Koreans, however; no information in other populations is available. An open clinical trial study was designed to evaluate the efficacy and safety in real life of a fixed-dose of Mirodenafil in Mexican patients with erectile dysfunction. Forty-seven male patients received a 100 mg tablet of Mirodenafil, during 12 weeks. Primary outcome efficacy measure was the percentage of male patients with successful intercourse. Secondary outcomes measures included patient satisfaction, mood and self-esteem level. Safety assessments included laboratory tests, vital signs, physical examination, 12-lead electrocardiogram recordings, and incidence of adverse events by patients. Oral administration of Mirodenafil improved in an 80% -90% the number of successful intercourses from 7 to 84 days of treatment. Moreover, patients reported a significant increment in their sexual satisfaction, mood and self-esteem. Mirodenafil treatment did not modify vital signs nor anthropometric parameters during 84 days. Mild headache was the most frequent adverse event (17.0%) and there were no severe adverse events during pharmacological treatment. Data suggest that oral Mirodenafil is safety, well tolerated and effective in the Mexican population with erectile dysfunction
Efficacy and safety of the metformin-mazindol anorectic combination in rat
The current study investigates the anorectic interaction and safety of the mazindol-metformin combination in rats. Isobologram and interaction index were used to determine anorectic interaction between mazindol and metformin in the sweetened milk model. The safety profile of the mazindol-metformin combination was determined by measuring anxiety, blood pressure, hematic biometry and blood chemistry. An acute dose of mazindol and metformin administered per os, individually or as a mixture, has reduced the milk consumption in rats in a dose-dependent manner. Theoretical effective dose 40 (ED40t) did not differ from the experimental effective dose 40 (ED40e) obtained with the mazindol-metformin mixture in the anorexia experiments, by Student´s t-test. In addition, the interaction index confirmed the additive anorectic effect between both drugs. A single oral dose of ED40e mazindol-metformin mixture induced anxiolysis in the elevated plus-maze test. Moreover, oral administration of mazindol-metformin combination for 3 months significantly decreased glycemia, but not blood pressure nor other parameters of hematic biometry and blood chemistry. Results suggest that mazindol-metformin combination exerts an additive anorectic effect, as well as anxiolytic and hypoglycemic properties. Mazindol-metformin combination might be useful in obese patients with anxiety disorders or diabetes risk factors
CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma
CD229 is a cell-surface molecule predominantly expressed on lymphocytes. Its expression in B-cell malignancies is poorly known. We tested the presence of this immunoreceptor on a large number of malignancies and normal tissue using a new monoclonal antibody and tissue microarrays. Our data show that CD229 expression is restricted to hematopoietic cells. It was strongly expressed in myeloma and marginal-zone lymphomas. Because of the high expression on multiple myeloma cells, we also analyze the presence of soluble CD229 in the sera of these patients. We showed that serum levels of soluble CD229 in myeloma patients, at the time of diagnosis, could be useful as a prognostic biomarker. Altogether, our results indicate that CD229 represents not only a useful disease biomarker but also an attractive therapeutic target. CD229 (Ly9) homophilic receptor, which belongs to the SLAM family of cell-surface molecules, is predominantly expressed on B and T cells. It acts as a signaling molecule, regulating lymphocyte homoeostasis and activation. Studies of CD229 function indicate that this receptor functions as a regulator of the development of marginal-zone B cells and other innate-like T and B lymphocytes. The expression on leukemias and lymphomas remains poorly understood due to the lack of CD229 monoclonal antibodies (mAb) for immunohistochemistry application (IHC). In this study, we used a new mAb against the cytoplasmic region of CD229 to study the expression of CD229 on normal tissues and B-cell malignancies, including multiple myeloma (MM), using tissue microarrays. We showed CD229 to be restricted to hematopoietic cells. It was strongly expressed in all cases of MM and in most marginal-zone lymphomas (MZL). Moderate CD229 expression was also found in chronic lymphocyte leukemia (CLL), follicular (FL), classic mantle-cell (MCL) and diffuse large B-cell lymphoma. Given the high expression on myeloma cells, we also analyzed for the presence of soluble CD229 in the sera of these patients. Serum levels of soluble CD229 (sCD229) at the time of diagnosis in MM patients could be useful as a prognostic biomarker. In conclusion, our results indicate that CD229 represents not only a useful biomarker but also an attractive therapeutic target
Lo tangible e intangible del diseño
1 archivo PDF (366 páginas)"El Departamento de Evaluación del Diseño, en el Tiempo de la División de Ciencias y Artes para el Diseño de la Universidad Autónoma Metropolitana, Azcapotzalco, publica este libro colectivo, donde se aborda la discusión y el análisis sobre "Lo tangible e intangible del diseño". Este libro tiene como finalidad el profundizar en distintas posiciones teóricas, metodológicas y empíricas, donde un grupo interdisciplinario de profesores investigadores del Departamento de Evaluación, desde la arquitectura, los estudios urbanos, la educación, la historia, la semiótica, el diseño de la comunicación gráfica y el industrial; buscan convergencias y discuten divergencias que puedan generar servir como referentes intelectuales y teóricos, en el diseño. Este libro es resultado del Cuarto Coloquio Departamental: Lo tangible e Intangible del Diseño. Evaluación de Objetos, Espacios, Mensajes, realizado durante el mes de septiembre del año 2004, el cual se constituyó como un espacio para el intercambio de experiencias académicas y profesionales, desde una perspectiva interdisciplinaria, centrada en la reflexión y la discusión sobre la manera de cómo se puede analizar, definir y evaluar, lo tangible y lo intangible en el diseño"
Research Group on Earth Observation, Geological Risks and Climate Change (OBTIER)
[EN] Within the framework of the IGME-CSIC Department of Geological Hazards and Climate Change, the OBTIER research group was created in July 2021 and currently has 22 members, including scientific and technical staff, as well as young people with contracts linked to competitive national and international research projects. The main objective of the group is to provide society with scientific information, methods, tools and solutions to mitigate the impact of geohazards and the effects of Climate Change. OBTIER is currently leading 6 competitive projects (4 European and 2 national), as well as several projects in agreement with other national and international administrations. It is an active member of the EuroGeoSurveys Earth Observation Expert Group and the ASGMI Geological Hazards Group. OBTIER offers society a wide range of capabilities on: earthquakes, tsunamis, landslides, land subsidence, volcanic eruptions, droughts and floods. In 2021, the group published an article in Science entitled: Mapping the global threat of land subsidence with significant media coverage around the world.Peer reviewe
Seminario de Economía Mexicana
Serie de ponencias referentes al Seminario de Economía Mexicana. Memorias del Seminario de Economía Mexicana de 199
R.H. Moreno-Durán: fantasía y verdad. Valoración múltiple
Pocos escritores colombianos han explorado diversos géneros literarios con resultados satisfactorios; Moreno-Durán destaca en el panorama artístico de Colombia al cosechar logros en una amplia producción creativa que incluye novelas, cuentos, ensayos y en los últimos tiempos el teatro. / Contenido. Preliminares; Capítulo 1 - R.H. Moreno-Durán: a fondo; Capítulo 2 - R.H. Moreno-Durán: en breve; Anexos
Consenso colombiano de enfermedad inflamatoria intestinal
La Enfermedad inflamatoria intestinal (EEI) es un término con el que se conocen varias
entidades, las dos más importantes: la colitis ulcerativa idiopática (CUI) y la enfermedad de Crohn (EC), cuyo origen es multifactorial y se caracterizan por un fenómeno
inflamatorio, crónico, recurrente, con diferentes grados de severidad del tubo digestivo;
pero, además con afectación potencial de otros órganos.
En la última década ha habido un renovado interés en dichas entidades, debido a un
auge en medicamentos novedosos; a pesar de lo cual estas siguen siendo incurables.
Lo anterior asociado a una incidencia creciente de dicha patología en nuestro país nos
obliga tanto científica como moralmente a convocar a un panel de expertos para elaborar unos lineamientos básicos en el enfoque y manejo de la EEI.
OBJETIVOS
1. Desarrollar un consenso adaptado a nuestro medio, basado en documentación científica de la mejor calidad disponible para el enfoque diagnóstico y el manejo médico
y quirúrgico.
2. Publicar y difundir dichos lineamentos tanto a la comunidad científica como al
público en general a través de foros especializados, y medios de comunicación de
alta penetración.
3. Elaborar y divulgar el consenso en forma de suplemento de la Revista Colombiana
de Gastroenterología, el 8 de diciembre de 2011, en medio del congreso de ACADI
(Asociación Colombiana de Asociaciones del Aparato Digestivo); es el mejor homenaje que el panel multidisciplinario de expertos le puede rendir a dicho evento; pero
más importante aún es el reconocimiento que se le hace a los pacientes que padecen
de dicha patología en nuestro país, quienes en últimas son nuestra razón de ser.
METODOLOGÍA
1. Se invitaron médicos especialistas (Clínicos y quirúrgicos), líderes de opinión e
industria farmacéutica nacional, cuyo área de interés y de trabajo es la EEI.
2. Se separó y manejó independientemente desde el principio la CUI de la EC. A su
vez, se dividió cada entidad por módulos, con base en el método de panel de Delphi,
se nombró un coordinador por cada uno de ellos, el cual se encargó de analizar junto
con su equipo la literatura, para extraer el nivel de evidencia clínica y así emitir unos conceptos preliminares. Posteriormente, todo el panel de expertos se reunió en
varias jornadas y conjuntamente se revisó nuevamente la evidencia clínica y conclusiones de los diferentes módulos homogenizándolas y de una manera concertada se
formularon las recomendaciones definitivas.Q4https://orcid.org/0000-0002-9219-4548Revista Nacional - Indexad
- …